Elite Pharmaceuticals, Inc. (ELTP) reported first-quarter fiscal 2026 revenues of $40.2 million for the period ending June 30, 2025, marking a 113.9% year-over-year increase from $18.8 million. The company also saw a significant rise in manufacturing fees, up 115.7% to $39.8 million. Despite this growth, Elite posted a net loss of $5.9 million (or $0.01 per share), compared to a net income of $0.6 million in the same quarter last year due to a $22.1 million non-cash charge related to warrants.
Operating expenses increased by 19.9% year over year to $5.5 million, while gross profit surged 221.3% to $27.2 million, with gross margin expanding to 68%. The company ended the quarter with $21.7 million in cash, up from $11.3 million at the end of March 2025.
Management attributed the revenue boom to growth in its Elite label products and new launches like lisdexamfetamine. Although the company did not issue formal guidance for fiscal 2026, it plans to focus on expanding generics in high-value therapeutic areas.
